These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30815390)

  • 1. Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets.
    Saada-Bouzid E; Le Tourneau C
    Front Oncol; 2019; 9():74. PubMed ID: 30815390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Patel B; Saba NF
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on cetuximab in squamous cell carcinoma of the head and neck.
    Frampton JE
    BioDrugs; 2011 Apr; 25(2):129-33. PubMed ID: 21443275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications.
    Langer CJ
    Cancer; 2008 Jun; 112(12):2635-45. PubMed ID: 18442098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Zibelman M; Mehra R
    Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab in the treatment of head and neck cancer.
    Bernier J
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1539-52. PubMed ID: 17134359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.
    Egloff AM; Grandis JR
    J Oncol; 2009; 2009():896407. PubMed ID: 19636423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
    Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiepidermal growth factor receptor therapy in squamous cell carcinoma of the head and neck.
    Shaib W; Kono S; Saba N
    J Oncol; 2012; 2012():521215. PubMed ID: 22778735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.
    Argiris A; Bauman JE; Ohr J; Gooding WE; Heron DE; Duvvuri U; Kubicek GJ; Posluszny DM; Vassilakopoulou M; Kim S; Grandis JR; Johnson JT; Gibson MK; Clump DA; Flaherty JT; Chiosea SI; Branstetter B; Ferris RL
    Ann Oncol; 2016 Aug; 27(8):1594-600. PubMed ID: 27177865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
    Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role?
    Alorabi M; Shonka NA; Ganti AK
    Crit Rev Oncol Hematol; 2016 Mar; 99():170-9. PubMed ID: 26797287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Taberna M; Oliva M; Mesía R
    Front Oncol; 2019; 9():383. PubMed ID: 31165040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab.
    Kono SA; Haigentz M; Yom SS; Saba N
    Chemother Res Pract; 2012; 2012():901320. PubMed ID: 23056941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
    Bernier J
    Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck.
    Simpson DR; Mell LK; Cohen EE
    Oral Oncol; 2015 Apr; 51(4):291-8. PubMed ID: 25532816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
    Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
    Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.